Last updated: July 2, 2026
ViiV Healthcare Company v. Lupin Limited (1:17-cv-00315): litigation summary, claims at issue, and exclusivity impact
Executive summary. Case ViiV Healthcare Company v. Lupin Limited, 1:17-cv-00315 is a US Hatch-Waxman patent infringement dispute brought by ViiV Healthcare against Lupin tied to ANDA generic entry for a ViiV HIV product. The litigation’s commercial relevance is that an ANDA would be blocked unless Lupin could secure a non-infringing finding, a patent invalidation, or a settlement permitting earlier launch. The available prompt does not include docket content, asserted patents, claim construction outcomes, or settlement terms, so a complete, accurate litigation summary cannot be produced.
What patents were asserted in ViiV Healthcare Company v. Lupin Limited 1:17-cv-00315?
A proper litigation summary requires the asserted US patent numbers, claim(s) asserted, and which ANDA submission (and corresponding FDA drug listing) triggered the case. Without the complaint or docket index containing asserted patents and relevant ANDA details, the patent-at-issue set cannot be stated accurately.
Which drug and ANDA does 1:17-cv-00315 connect to?
Hatch-Waxman cases typically map to:
- the FDA Reference Listed Drug (RLD) and strength(s),
- the ANDA applicant,
- the paragraph (often Paragraph IV), and
- the Orange Book-listed patents tied to the RLD.
No docket or FDA mapping is provided in the prompt, so the drug linkage and Orange Book patent list cannot be reproduced reliably.
Who sued whom and what was Lupin’s legal posture in 1:17-cv-00315?
A litigation analysis should cover:
- ViiV’s theories (direct infringement, induced infringement, contributory infringement),
- Lupin’s defenses (non-infringement, invalidity under §§101/102/103/112, unenforceability, lack of statutory basis),
- whether Lupin filed counterclaims, and
- any stipulated dismissal of claims or narrowing at claim construction.
No filings, answers, counterclaims, scheduling orders, or motions are included in the prompt, so these items cannot be stated.
What claim construction rulings and dispositive motions were decided in 1:17-cv-00315?
Claim construction outcomes often determine:
- which product features determine infringement (e.g., formulation parameters, dosing regimen, release profile, or compound identity),
- whether certain asserted claims fail as a matter of law,
- the trajectory of summary judgment or trial.
The prompt contains no Markman order, claim construction record, summary judgment rulings, or trial disposition, so a decision-based analysis cannot be completed.
When did the parties reach settlement or dismissal in 1:17-cv-00315?
For business planning, the timeline matters:
- filing date of the complaint,
- service and answer dates,
- Phase I and Phase II procedural milestones,
- any settlement agreement and its effective date,
- any stipulations of dismissal and the “launch authorization” terms.
The prompt provides only the case caption and docket number, not the procedural history, so settlement timing cannot be reported.
What is the Orange Book status of the patents tied to ViiV’s RLD in 1:17-cv-00315?
A litigation-to-Orange-Book mapping requires:
- RLD name,
- ANDA paragraph type (IV/NIV),
- Orange Book patent list (drug substance, drug product, method-of-use),
- patent expiration and pediatric exclusivity extensions, and
- any listed terminal disclaimers.
The prompt provides no Orange Book listing or asserted-patent numbers, so status and exclusivity calculations cannot be performed.
How does 1:17-cv-00315 affect generic launch risk for Lupin and other filers?
To assess generic launch risk, the analysis must connect:
- the asserted patents’ legal strength,
- whether those patents were held invalid or not infringed,
- whether any injunctions were entered,
- any settlement that delays launch, and
- whether there are remaining unasserted patents that still block launch.
No outcomes or remaining asserted/unasserted patents are given, so launch-risk conclusions would be speculative.
What biosimilar risk applies, if any, in 1:17-cv-00315?
Hatch-Waxman disputes are typically small molecules; biosimilar disputes fall under BPCIA (Biologics Price Competition and Innovation Act) and BLA pathways. Determining whether this case is biosimilar-related requires knowing the therapeutic modality and FDA pathway.
The prompt does not identify the drug class or mechanism, so biosimilar risk analysis cannot be anchored.
What manufacturing or formulation/IP barriers were litigated in 1:17-cv-00315?
For HIV small molecules, infringement often turns on:
- chemical identity,
- polymorph/formulation selection,
- bioequivalence-related features,
- release characteristics,
- or method-of-use/dosing claims.
No claim chart content, infringement theory, or product design differences are provided, so formulation/manufacturing barrier analysis is not possible.
How strong is the ViiV patent estate versus Lupin’s potential non-infringement/invalidity arguments in 1:17-cv-00315?
A strength assessment requires:
- which patents were asserted,
- their remaining term,
- whether priority dates were challenged,
- litigation outcomes (invalidated vs survived),
- enablement/indefiniteness positions,
- and any appellate posture.
The prompt contains no asserted patents or outcomes.
Which court decided the case and what procedural posture matters for appeal in 1:17-cv-00315?
High-level litigation analytics typically include:
- district court judge,
- venue and procedural posture,
- any interlocutory appeals (rare in Hatch-Waxman but possible for injunctions),
- motions for preliminary injunction,
- and final judgment date.
No court or dates are provided in the prompt beyond the docket number.
Key Takeaways
- A complete litigation summary and analysis cannot be produced from the provided information, because it lacks the asserted patent list, filings/motions, claim construction, dispositive outcomes, and any settlement or dismissal terms.
- Business impact can’t be quantified (launch date exposure, injunction risk, or remaining blocking patents) without docket and Orange Book linkage.
FAQs
- What is the typical Hatch-Waxman structure of a ViiV vs. Lupin case like 1:17-cv-00315?
- How do Paragraph IV certifications shape the litigation timeline in generic HIV ANDA disputes?
- What documents contain the asserted patent list and infringement theories in district court dockets?
- How is launch “authorized” in Hatch-Waxman settlements tied to patent expiry and agreed dates?
- What are the main invalidity categories (Sections 101, 102, 103, 112) litigated in ANDA patent cases?
References
- Fed. R. Civ. P. 16; Hatch-Waxman framework overview (general).
- 35 U.S.C. §§ 101, 102, 103, 112 (general).
